Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Current Signal: SELL (auto-tracking)
0.00% $12.41
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 1 620.93 mill |
EPS: | -0.0500 |
P/E: | -248.20 |
Earnings Date: | Apr 29, 2024 |
SharesOutstanding: | 130.62 mill |
Avg Daily Volume: | 2.000 mill |
RATING 2024-03-28 |
---|
A |
Buy |
RATINGS | ||
---|---|---|
Rating CashFlow: | Buy | |
Return On Equity: | Neutral | |
Return On Asset: | Buy | |
DE: | Buy | |
P/E: | Strong Buy | |
Price To Book: | Neutral |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -248.20 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-5.20x |
Company: PE -248.20 | industry: PE 47.78 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 12.06 - 12.76 ( +/- 2.84%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-16 | Burgess Justin | Buy | 20 000 | Stock Options (Right to Buy) |
2024-03-01 | Burgess Justin | Buy | 2 767 | Common Stock |
2024-03-01 | Burgess Justin | Buy | 4 334 | Common Stock |
2024-03-01 | Burgess Justin | Sell | 7 101 | Common Stock |
2024-03-01 | Burgess Justin | Sell | 4 334 | Stock Options (Right to Buy) |
INSIDER POWER |
---|
-19.45 |
Last 100 transactions |
Buy: 1 161 830 | Sell: 2 152 314 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $12.41 (0.00% ) |
Volume | 1.332 mill |
Avg. Vol. | 2.000 mill |
% of Avg. Vol | 66.62 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $12.92 | N/A | Active |
---|
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.